{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:08:49Z","timestamp":1790806129777,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T00:00:00Z","timestamp":1586131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.ctro.2020.04.003","type":"journal-article","created":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T17:42:16Z","timestamp":1586281336000},"page":"83-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["PD-L1 induction in tumor tissue after hypofractionated thoracic radiotherapy for non-small cell lung cancer"],"prefix":"10.1016","volume":"22","author":[{"given":"Jaanika","family":"Narits","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes","family":"Tamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Jaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2020.04.003_b0005","article-title":"Patterns of survival and surgical treatment in lung cancer patients in Estonia by histologic type and stage, 1996\u20132016","volume":"1\u20138","author":"Innos","year":"2019","journal-title":"Acta Oncol."},{"key":"10.1016\/j.ctro.2020.04.003_b0010","doi-asserted-by":"crossref","unstructured":"Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology. 2018;29:iv192-iv237.","DOI":"10.1093\/annonc\/mdy275"},{"key":"10.1016\/j.ctro.2020.04.003_b0015","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"New England J Med"},{"key":"10.1016\/j.ctro.2020.04.003_b0020","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.prro.2011.01.005","article-title":"Palliative thoracic radiotherapy in lung cancer: an American Society for Radiation Oncology evidence-based clinical practice guideline","volume":"1","author":"Rodrigues","year":"2011","journal-title":"Pract Radiat Oncol."},{"key":"10.1016\/j.ctro.2020.04.003_b0025","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ctro.2020.04.003_b0030","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.2147\/OTT.S199176","article-title":"Neutrophil-lymphocyte ratio (NLR) predicted prognosis for advanced non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB)","volume":"12","author":"Ren","year":"2019","journal-title":"Onco Targets Therapy"},{"key":"10.1016\/j.ctro.2020.04.003_b0035","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41571-019-0173-9","article-title":"Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC","volume":"16","author":"Camidge","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctro.2020.04.003_b0040","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"New England J Med"},{"key":"10.1016\/j.ctro.2020.04.003_b0045","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ctro.2020.04.003_b0050","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20040824","article-title":"Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers","volume":"20","author":"Pawelczyk","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctro.2020.04.003_b0055","doi-asserted-by":"crossref","first-page":"20090","DOI":"10.1038\/srep20090","article-title":"Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer","volume":"6","author":"Sheng","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctro.2020.04.003_b0060","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00432-018-2642-4","article-title":"Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients","volume":"144","author":"Rojko","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctro.2020.04.003_b0065","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/CJI.0000000000000275","article-title":"Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer","volume":"42","author":"Guo","year":"2019","journal-title":"J Immunother."},{"key":"10.1016\/j.ctro.2020.04.003_b0070","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.4143\/crt.2018.537","article-title":"Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer","volume":"51","author":"Shin","year":"2019","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.ctro.2020.04.003_b0075","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40425-018-0361-7","article-title":"Radiation therapy and PD-1\/PD-L1 blockade: the clinical development of an evolving anticancer combination","volume":"6","author":"Gong","year":"2018","journal-title":"J ImmunoTher Cancer"},{"key":"10.1016\/j.ctro.2020.04.003_b0080","doi-asserted-by":"crossref","first-page":"80506","DOI":"10.18632\/oncotarget.19193","article-title":"Radiation alters PD-L1\/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK\/Erk signaling pathway","volume":"8","author":"Shen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctro.2020.04.003_b0085","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.87415","article-title":"Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer","volume":"1","author":"Herter-Sprie","year":"2016","journal-title":"JCI insight"},{"key":"10.1016\/j.ctro.2020.04.003_b0090","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jtho.2017.04.014","article-title":"Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer","volume":"12","author":"Gong","year":"2017","journal-title":"J Thoracic Oncol"},{"key":"10.1016\/j.ctro.2020.04.003_b0095","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cllc.2017.06.015","article-title":"Combination Therapy of Radiotherapy and Anti-PD-1\/PD-L1 Treatment in Non-Small-cell Lung Cancer: A Mini-review","volume":"19","author":"Takamori","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctro.2020.04.003_b0100","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2020.04.003_b0105","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","article-title":"Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer","volume":"2","author":"McLaughlin","year":"2016","journal-title":"JAMA oncology."}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630820300288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630820300288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:07:40Z","timestamp":1762502860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630820300288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":21,"alternative-id":["S2405630820300288"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2020.04.003","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-L1 induction in tumor tissue after hypofractionated thoracic radiotherapy for non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2020.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}]}}